In the eyes of Amylyx Pharmaceuticals, Inc. co-CEOs Josh Cohen and Justin Klee, a lot has happened since a US Food and Drug Administration advisory committee narrowly recommended against approval of the company’s amyotrophic lateral sclerosis drug in late March.
In the five-plus month interval between that meeting on AMX0035 and a planned second review by the Peripheral and Central...





